Neurocrine Biosciences — May 5, 2026 release

drome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO , May 5, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026. “Neurocrine’s strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “We delivered $811 million in net product sales, representing 44% year-over-year growth, driven by continued strong demand for INGREZZA and CRENESSITY ® (crinecerfont). Our recently announced agreement to acquire Soleno Therapeutics further underscores our commitment to address conditions with significant unmet need and accelerate revenue growth. With multiple first-in-class commercial medicines and the deepest pipeline in our history, Neurocrine is well-positioned to deliver transformative therapies for patients and drive sustained growth.” Net Product Sales Highlights • Total first-quarter 2026 net product sales were $811.0 million, representing 44% growth year-over-year. • INGREZZA first-quarter 2026 net product sales were $656.9 million, representing 20% growth year-over-y